A humanized IgG1 monoclonal antibody that was designed to maximize clinical performance and minimize potential impact from undesirable product quality attributes. It is intended as a treatment for non-Hodgkin’s Lymphoma (NHL), in an adult population only, and its mechanism of action is B cell killing primarily through ADCC.